Amended Statement of Beneficial Ownership (sc 13d/a)
26 Mars 2021 - 10:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED
IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(a)
AND AMENDMENTS THERETO FILED PURSUANT TO
§ 240.13d-2(a)
(Amendment No. 3)1
Summit Therapeutics Inc.
(Name
of Issuer)
Common Stock, par value $0.01
per share
(Title of Class of Securities)
86627T108
(CUSIP Number)
ADAM W.
FINERMAN, ESQ.
OLSHAN
FROME WOLOSKY LLP
1325
Avenue of the Americas
New
York, New York 10019
(212)
451-2300
(Name, Address and Telephone Number of Person
Authorized to Receive Notices
and Communications)
March 24, 2021
(Date of Event Which Requires
Filing of This Statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following
box ¨.
Note: Schedules
filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See
§ 240.13d-7 for other parties to whom copies are to be sent.
1
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.
The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSON
|
|
|
|
|
|
|
|
|
|
|
ROBERT W. DUGGAN
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☐
|
|
|
|
|
(b) ☐
|
|
|
|
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
SOURCE OF FUNDS
|
|
|
|
|
|
|
|
|
|
|
PF
|
|
|
5
|
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
|
☐
|
|
|
|
|
|
|
|
|
|
|
|
|
6
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
|
|
|
|
|
|
|
U.S.A.
|
|
NUMBER OF
|
|
7
|
|
SOLE VOTING POWER
|
|
SHARES
|
|
|
|
|
|
BENEFICIALLY
|
|
|
|
|
60,281,588*
|
|
OWNED BY
|
|
8
|
|
SHARED VOTING POWER
|
|
EACH
|
|
|
|
|
|
REPORTING
|
|
|
|
|
- 0 -
|
|
PERSON WITH
|
|
9
|
|
SOLE DISPOSITIVE POWER
|
|
|
|
|
|
|
|
|
|
|
|
|
60,281,588*
|
|
|
|
10
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
|
|
|
|
|
|
|
- 0 -
|
|
|
11
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
|
|
|
|
|
|
60,281,588*
|
|
|
12
|
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐
|
|
|
|
|
|
|
|
|
|
|
|
|
13
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
|
|
|
|
|
|
|
|
69.37%*
|
|
|
14
|
|
TYPE OF REPORTING PERSON
|
|
|
|
|
|
|
|
|
|
|
IN
|
|
* The 60,281,588 shares of Common Stock beneficially owned consist
of (i) 42,224,677 shares of Common Stock, (ii) 14,071,856 shares of Common Stock, representing the number of shares of Common Stock
the Reporting Person purchased pursuant to the Purchase Agreement (as defined below) and (iii) includes the exercise of warrants
to buy 3,985,055 shares of Common Stock, which are exercisable until December 24, 2029.
The following constitutes
the Schedule 13D/A filed by the undersigned (as amended hereby, the “Schedule 13D”).
|
Item 5.
|
Interests in Securities of the Issuer.
|
Items 5(a) –
(b) are hereby amended and restated to read as follows:
The aggregate percentage
of Common Stock reported owned by the Reporting Person is based on 82,916,189 shares of Common Stock outstanding as of March 23,
2021 based on the Issuer’s most recent calculation.
|
(a)
|
As of the close of business on March 24, 2021, through the holding of (i) 56,296,533 shares of
Common Stock and (ii) warrants to purchase 3,985,055 shares of Common Stock, the Reporting Person beneficially owned 60,281,588
shares of Common Stock (the “Shares”). Shares held by the Reporting Person include shares held in his retirement
accounts.
|
Percentage: Approximately
69.37%.
|
(b)
|
1. Sole power to vote or direct: 60,281,588
|
2. Shared power to
vote or direct: 0
3. Sole power to dispose
of or direct the disposition of: 60,281,588
4. Shared power to
dispose of or direct the disposition of: 0
|
Item 6.
|
Contracts, Arrangements, Undertakings or Relationships with Respect to Securities of the Issuer.
|
Item 6 is hereby amended
to add the following:
On March 24, 2021,
the Reporting Person purchased from the Issuer, and the Issuer sold and issued to the Reporting Person a Promissory Note (the “Note”)
in the original principal amount of $55,000,000, which Note shall mature and become due upon the earlier of (i) the consummation
of a public offering of securities registered under the Securities Act of 1933, as amended, by the Issuer with net proceeds of
no less than $55,000,000 or (ii) thirteen (13) months from the date of the Note, upon the terms and conditions set forth in such
Note. As more described in the Note Purchase Agreement, the Reporting Person shall have the right to participate in a subsequent
Issuer equity financing transaction for up to a portion of such transaction that represents the Reporting Person’s percentage
ownership of the Issuer’s issued and outstanding equity. To the extent that the Note remains outstanding, the Reporting Person
may apply the principal of the Note to the purchase price of any such investment.
|
Item 7.
|
Material to be Filed as Exhibits.
|
|
99.1
|
Note Purchase Agreement, dated March 24, 2021, by and between the Issuer and the Reporting Person
(incorporated by reference to Exhibit 10.1 of the Issuer’s Form 8-K filed on March 26, 2021).
|
|
99.2
|
Promissory Note, dated March 24, 2021, by and between the Issuer and the Reporting Person (incorporated
by reference to Exhibit 10.2 of the Issuer’s Form 8-K filed on March 26, 2021).
|
SIGNATURES
After reasonable inquiry
and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true,
complete and correct.
Dated: March 26, 2021
|
|
|
|
|
/s/ Robert W. Duggan
|
|
Robert W. Duggan
|
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024